FEB 28 2027
LEO Pharma — dersimelagon
for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) in adults
Accepted SEP 18 2026.
Pivotal trial
To investigate the efficacy of MT-7117 on time to onset and severity of first prodromal symptoms (burning, tingling, itching, or stinging) associated with sunlight exposure in adults and adolescents with EPP or XLP.
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on dersimelagon
- FDA accepts Tanabe’s NDA for dersimelagon - The Pharma Letter
- Dersimelagon Gains FDA Priority Review for EPP, XLP - HCPLive
- FDA grants priority review to dersimelagon for erythropoietic protoporphyria and X-linked protoporphyria - Contemporary Pediatrics
- Dersimelagon NDA Accepted by FDA with Priority Review for EPP, XLP - Dermatology Times
- LEO Pharma Announces FDA Acceptance of Dersimelagon NDA with Priority Review and Closes Acquisition from Tanabe Pharma - BioSpace